Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 6/20 | 0.73 |
| ▸ | OXTR | P30559 | 5/20 | 0.73 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.44 |
| ▸ | FFAR2 | O15552 | 7/20 | 0.41 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4936752 | 1.00 | AVPR1A (0.73) | AVPR1AOXTRAVPR2FFAR2SLC6A7 | |
| SCHEMBL5036670 | 0.92 | AVPR1A (0.79) | AVPR1AOXTRAVPR2FFAR2SLC6A7 | |
| SCHEMBL5034150 | 0.92 | AVPR1A (0.79) | AVPR1AOXTRAVPR2FFAR2SLC6A7 | |
| SCHEMBL29449382 | 0.92 | AVPR1A (0.79) | AVPR1AOXTRAVPR2FFAR2SLC6A7 | |
| SCHEMBL4416107 | 0.92 | AVPR1A (0.79) | AVPR1AOXTRAVPR2FFAR2SLC6A7 | |
| SCHEMBL24313450 | 0.92 | AVPR1A (0.79) | AVPR1AOXTRAVPR2FFAR2SLC6A7 | |
| SCHEMBL5570187 | 0.91 | AVPR1A (0.69) | AVPR1AOXTRAVPR2FFAR2SLC6A7 | |
| SCHEMBL5570185 | 0.91 | AVPR1A (0.69) | AVPR1AOXTRAVPR2FFAR2SLC6A7 | |
| SCHEMBL5473608 | 0.91 | AVPR1A (0.69) | AVPR1AOXTRAVPR2FFAR2SLC6A7 | |
| SCHEMBL5566381 | 0.91 | AVPR1A (0.77) | AVPR1AOXTRAVPR2FFAR2SLC6A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725526-B1 | METHOD FOR PREPARING PYRROLIDINE OXIMES | SERONO LAB (CH) | 2007-12-12 | — | — | EP | disclosed |
| US-20070197794-A1 | Method for preparing pyrrolidine oximes | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2007-08-23 | — | — | US | disclosed |
| EP-1268418-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS | Applied Research Systems ARS Holding N.V. (AN) | 2003-01-02 | — | — | EP | disclosed |
| EP-1268419-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BAX INHIBITORS | Applied Research Systems ARS Holding N.V. (AN) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001074769-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-10-11 | — | — | WO | disclosed |
| WO-2001072705-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197794-A1 | Method for preparing pyrrolidine oximes | PPOX, PGF, OXTR | AVPR1A 398/4885OXTR 3/4885AVPR2 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.